NEW YORK (GenomeWeb) – MDxHealth has exclusively licensed Ghent University's proprietary molecular diagnostic visualization technology to enable the detection of cancer associated epigenetic changes in both tissue and liquid samples, the company said today.

Separately, the two parties forged a research and development agreement to develop in vitro diagnostic kits and laboratory-developed tests based on the technology.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.